Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE SME |
| SME IPO Issue Type | Fixed Price Issue |
| Total Issue Size | ₹49.26 Cr |
| Reserved for Market Maker | ₹2.50 Cr |
| Net Issue Size | ₹49.26 Cr |
| Fresh Issue | ₹42.26 Cr |
| Offer for Sale | ₹4.51 Cr |
| Face Value | ₹10 Per Equity Share |
| Issue Price | ₹135.00 per share |
| BSE Code | 544549 |
| Registrar | Skyline Financial Services Pvt.Ltd. |
| Lead Managers | Sarthi Capital Advisors Pvt.Ltd. |
| Allotment Status |
| DRHP |
| Final Prospectus |
 ₹0 A/C OpeningFree MF ₹20F&O Trade ₹0Delivery 1Cr+Customers Open Free Account → |
 ₹0 A/C Opening₹0 AMC Trading Account ₹20F&O Trade ₹20Delivery FreeIPO Apply Open Free Account → |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 2,000 shares · Multiples of 1,000 shares
Earkart Limited is a HealthTech platform, specializing in hearing aids and related accessories. It offers modern hearing devices, like Receiver-In-Canal (RIC), Invisible (IIC), Behind-The-Ear (BTE), In-The-Ear (ITE), In-The-Canal (ITC) and Completely-In-Canal (CIC).
It also offers and distributes other products like adjustable foldable walkers and Multi-Sensory Integrated Educational Development (MSIED) and Teaching Learning Material (TLM) for physically challenged.
The company sells products through a network of partners and clinics, both domestically and globally. It is also a trusted Government e-Market (GeM) supplier of hearing aids to ALIMCO under Ministry of Social Justice and Empowerment.
In April 2024, the company has launched Shop in Shop (SIS) model, wherein it offers franchise to opticians and ENT/optical clinics. As on date, the company operates 49 SIS clinics across 22 cities in 6 states and 2 Union Territories, i.e., Haryana, Uttar Pradesh, Rajasthan, Punjab, Jharkhand, Delhi, Uttarakhand, and Chandigarh.
Its manufacturing facility is located in Noida, across 4,500 square feet
Competitive Strengths:
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding incremental working capital requirements of Company | 21.10 |
| 2 | Funding capital expenditure requirements for setting of Shop in Shop (SIS) Business Model in ENT/Ophthalmic Clinics across India and Setting up of Infrastructure for operational activities | 17.33 |
| 3 | General Corporate Purposes | 0.63 |
| 4 | Issue Expenses | 6.26 |
| Total | 45.33 |
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 30.29 | 19.25 | 14.73 |
| Total Income | 43.19 | 31.97 | 28.97 |
| Profit After Tax | 6.88 | 3.06 | 1.31 |
| EBITDA | 9.76 | 3.55 | 1.61 |
| NET Worth | 19.92 | 13.03 | 6.56 |
| Reserves and Surplus | 9.48 | 12.97 | 6.49 |
| Total Borrowing | 4.96 | 4.00 | 1.21 |
| Amount in ₹ Crore | |||
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 34.55% |
| ROCE | 47.32% |
| Debt / Equity | 0.26% |
| RoNW | 34.55% |
| PAT Margin | 15.93% |
| EBITDA Margin | 22.65% |
| Price to Book Value | 7.08 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 6.59 | 5.00 |
| P/E (x) | 20.48 | 26.98 |
| Promoter Holding | 78.75% | 57.34% |
| Market Cap | ₹185.68 Cr. | |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Lead Manager Fees including Underwriting Commission | 5.55 |
| 2 | Fees Payable to Registrar to the Offer | 0.03 |
| 3 | Fees Payable Advertising, Marketing Expenses and Printing Expenses | 0.35 |
| 4 | Fees Payable to Regulators including Stock Exchanges and other Intermediaries | 0.10 |
| 5 | Fees payable to Legal Advisors | 0.07 |
| 6 | Fees payable to Peer Review Auditor | 0.03 |
| 7 | Fees Payable to Market Maker (for three years) | 0.09 |
| 8 | Escrow Bank Fees | 0.05 |
Last Updated on 16-Jun-2026 18:10:14
